A Distinctive Immune Signature in Thrombocytopenic Sepsis
Journal of Thrombosis and Haemostasis (JTH) posted on LinkedIn:
”A distinctive immune signature in thrombocytopenic sepsis
By Maria Mulet, Rubén Osuna-Gómez, Laura Martínez-España, Iris Artesero, Pol Duch Llorach, Paula Vera Artázcoz, Maria Torrens-Sonet, Nuria Rodriguez Farriolé, Noelia Villalta, Andrés Abril-Gamboa, Montserrat Seres, Elisabet Cantó, Ma. Àngels Ortiz, Joaquin Lopez-Contreras, and Silvia Vidal
Thrombocytopenic patients displayed hyperactivated PD-L1⁺ CXCR4⁺ platelets, dysfunctional neutrophil–platelet complexes, and elevated plasma MPO-DNA and S100A8/A9, signifying immune exhaustion despite pro-inflammatory signaling.
This platelet–neutrophil immunoparalysis phenotype links hemostatic dysregulation to organ failure risk, spotlighting PD-L1⁺ platelets and NET-associated markers as potential biomarkers or therapeutic targets in severe sepsis.
Read the article here.”
Title: A distinctive immunophenotypic signature in thrombocytopenic septic patients: platelet and neutrophil dysregulations as key contributors to disease severity
Authors: Maria Mulet, Rubén Osuna-Gómez, Laura Martínez-España, Iris Artesero, Pol Duch-Llorach, Paula Vera-Artázcoz, Maria Torrens-Sonet, Núria Rodríguez-Farré, Noelia Vilalta, Andrés Abril-Gamboa, Montserrat Seres, Elisabet Cantó, Ma. Àngels Ortiz, Joaquín López-Contreras, Silvia Vidal
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis